Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 369, Issue 4, pp 428–433 | Cite as

Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages

  • Takashi Ichiyama
  • Yoshiko Ueno
  • Masanari Hasegawa
  • Akihiro Niimi
  • Tomoyo Matsubara
  • Susumu Furukawa
Original Article


High-dose intravenous immunoglobulin (IVIG) therapy is well established as a standard therapy for Kawasaki disease (KD) that reduces the risk of developing coronary artery aneurysms. Activation of monocytes/macrophages and tumor necrosis factor-α (TNF-α) activity are responsible for severe vascular injury in acute KD. We examined whether or not IVIG inhibits TNF-α-induced activation of transcription factor NF-κB, a factor that is essential for the expression of proinflammatory cytokines, in human monocytic U-937 cells. The inhibitory effect of IVIG on NF-κB activation induced by TNF-α was evaluated by Western blotting and flow cytometry. In addition, we examined the effect of IVIG on the expression of FcγIII (CD16) and FcγRIIb (CD32b) in U-937 cells and peripheral blood CD14+ monocytes/macrophages by flow cytometry. Western blotting demonstrated that IVIG inhibits NF-κB activation in U-937 cells, and flow cytometry that IVIG inhibits NF-κB activation in U-937 cells in a dose-related manner. Western blotting of cytoplasmic extracts of U-937 cells revealed that IVIG inhibited degradation of the IκBα protein. Moreover, flow cytometry demonstrated that IVIG decreased the expression of FcγRIII in U-937 cells and peripheral blood CD14+ monocytes/macrophages. However, Western blotting revealed that IVIG did not affect the quantity of FcγRIII protein, and PCR that IVIG did not affect the quantity of FcγRIII mRNA in the cells. These findings suggest that IVIG inhibits TNF-α-induced NF-κB activation in monocytes/macrophages, and blocks FcγRIII on the membranes of monocytes/macrophages.


FcγRIIb FcγRIII Intravenous immunoglobulin Monocytes/macrophages NF-κB TNF-α 


  1. Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104 [Suppl 1]:10–20Google Scholar
  2. Andersson JP, Andersson UG (1990) Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 71:372–376PubMedGoogle Scholar
  3. Ariga S, Koga M, Takahashi M, Ishihara T, Matsubara T, Furukawa S (2001) Maturation of macrophages from peripheral blood monocytes in Kawasaki disease: immunocytochemical and immunoelectron macroscopic study. Pathol Int 51:257–263CrossRefPubMedGoogle Scholar
  4. Baeuerle PA, Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141–179PubMedGoogle Scholar
  5. Baldwin AS Jr (1996) The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649–683PubMedGoogle Scholar
  6. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U (1995) Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 267:1485–1488PubMedGoogle Scholar
  7. Chen CC, Rosenbloom CL, Anderson DC, Manning AM (1995) Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IκB-α phosphorylation. J Immunol 155:3538–3545PubMedGoogle Scholar
  8. Collart MA, Baeuerle P, Vassalli P (1990) Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 10:1498–1506PubMedGoogle Scholar
  9. Fujiwara H, Hamashima Y (1978) Pathology of the heart in Kawasaki disease. Pediatrics 61:100–107PubMedGoogle Scholar
  10. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, Kato H, Yabuta K (1988) Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48:247–251PubMedGoogle Scholar
  11. Furukawa S, Matsubara T, Jujoh K, Sasai K, Nakachi S, Sugawara T, Yabuta K, Kato H (1990) Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin. Eur J Pediatr 150:43–47PubMedGoogle Scholar
  12. Furukawa S, Imai K, Matsubara T, Yone K, Yachi A, Okumura K, Yabuta K (1992a) Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. Arthritis Rheum 35:672–677PubMedGoogle Scholar
  13. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K (1992b) Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum. Eur J Pediatr 151:44–47PubMedGoogle Scholar
  14. Furukawa S, Matsubara T, Yabuta K (1992c) Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child 67:706–708PubMedGoogle Scholar
  15. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K (1994) Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 124:721–725PubMedGoogle Scholar
  16. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, Kawarano M, Baba K, Baba K, Mori C (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2:1055–1058CrossRefPubMedGoogle Scholar
  17. Grimm S, Baeuerle PA (1993) The inducible transcription factor NF-κB: structure-function relationship of its protein subunits. Biochem J 290:297–308PubMedGoogle Scholar
  18. Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Neriah Y, Baeuerle PA (1993) Rapid proteolysis of IκB-α is necessary for activation of transcriptional factor NF-κB. Nature 365:182–185PubMedGoogle Scholar
  19. Hiscott J, Marois J, Garoufalis J, D’Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, Fenton M (1993) Characterization of a functional NF-κB site in the human interleukin 1β promotor: evidence for a positive autoregulatory loop. Mol Cell Biol 13:6231–6240PubMedGoogle Scholar
  20. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S (2001a) Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 45:44–47CrossRefPubMedGoogle Scholar
  21. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, Furukawa S (2001b) NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 99:373–377CrossRefPubMedGoogle Scholar
  22. Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S (2004) An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary artery in vitro. Inflamm Res (in press)Google Scholar
  23. Katayama K, Matsubara T, Fujiwara M, Koga M, Furukawa S (2000) CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin Exp Immunol 121:566–570CrossRefPubMedGoogle Scholar
  24. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R (1996) Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94:1379–1385PubMedGoogle Scholar
  25. Kawasaki T, Kosaki F, Ogawa S, Shigemitsu I, Yanagawa H (1974) A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54:271–276PubMedGoogle Scholar
  26. Koga M, Ishihara T, Takahashi M, Umezawa Y, Furukawa S (1998) Activation of peripheral blood monocytes and macrophages in Kawasaki disease: ultrastructural and immunocytochemical investigation. Pathol Int 48:512–517PubMedGoogle Scholar
  27. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR (1994) Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci USA 91:6288–6292PubMedGoogle Scholar
  28. Kunsch C, Lang RK, Rosen CA, Shannon MF (1994) Synergistic transcriptional activation of the IL-8 gene by NF-κB p65 (RelA) and NF-IL-6. J Immunol 153:153–164PubMedGoogle Scholar
  29. Lang GA, Silverman ED, Laxer RM, Lau AS (1989) Spontaneous tumor necrosis factor production in Kawasaki disease. Lancet 2:1298–1302PubMedGoogle Scholar
  30. Leung DY, Burns JC, Newburger JW, Geha RS (1987) Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79:468–472PubMedGoogle Scholar
  31. Leung DYM, Cotran RS, Kurt-Johnes E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. J Pediatr 115:939–943PubMedGoogle Scholar
  32. Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol 10:2327–2334PubMedGoogle Scholar
  33. Lin CY, Lin CC, Hwang B, Chiang B (1992) Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor α among patients with Kawasaki disease. J Pediatr 121:924–926PubMedGoogle Scholar
  34. Lin SY, Kinet JP (2001) Giving inhibitory receptors a boost. Science 291:445–446CrossRefPubMedGoogle Scholar
  35. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, Akira S (1993) Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 90:10193–10197PubMedGoogle Scholar
  36. Maury CPJ, Salo E, Pelkonen P (1988) Circulating interleukin-1β in patients with Kawasaki disease. N Engl J Med 319:1670–1671PubMedGoogle Scholar
  37. Maury CPJ, Salo E, Pelkonen P (1989) Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J Lab Clin Med 113:651–654PubMedGoogle Scholar
  38. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347PubMedGoogle Scholar
  39. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMedGoogle Scholar
  40. Pyatt DW, Stillman WS, Yang Y, Gross S, Zheng JH, Irons RD (1999) An essential role for NF-κB in human CD34+ bone marrow cell survival. Blood 93:3302–3308PubMedGoogle Scholar
  41. Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486CrossRefPubMedGoogle Scholar
  42. Sugawara T, Hattori S, Hirose S, Furukawa S, Yabuta K, Shirai T (1987) Immunopathology of the skin lesions of Kawasaki disease. In: Schulman ST (ed) Kawasaki disease. Liss, New York, pp 185–192Google Scholar
  43. Terai M, Kohno Y, Namba M, Umemiya T, Miwa K, Nakajima H, Mikata A (1990) Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 21:231–234PubMedGoogle Scholar
  44. Toungouz M, Denys CH, De Groote D, Dupont E (1995) In vitro inhibition of tumour necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 89:698–703PubMedGoogle Scholar
  45. Tridandapani S, Siefker K, Teillaud JL, Carter JE, Wewers MD, Anderson CL (2002) Regulated expression and inhibitory function of FcγRIIb in human monocytic cells. J Biol Chem 277:5082–5089CrossRefPubMedGoogle Scholar
  46. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J Biol Chem 272:31092–31099CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Takashi Ichiyama
    • 1
  • Yoshiko Ueno
    • 1
  • Masanari Hasegawa
    • 1
  • Akihiro Niimi
    • 2
  • Tomoyo Matsubara
    • 1
  • Susumu Furukawa
    • 1
  1. 1.Department of PediatricsYamaguchi University School of MedicineUbe, YamaguchiJapan
  2. 2.Bayer Yakuhin Ltd.Yodogawa-ku, OsakaJapan

Personalised recommendations